This product is a CRISPR/Cas9-edited polyclonal knockout cell population of the CAV1 gene in the Jurkat human T-lymphocyte cell line. The pool of edited cells carries disruptions of the endogenous CAV1 locus, leading to loss of caveolin-1 protein expression. This knockout model is provided as a bulk polyclonal population, suitable for studying the collective effects of heterogeneous gene edits without clonal isolation.
Jurkat cells are an immortalized T-lymphocyte line originally derived from the peripheral blood of a 14-year-old male with acute T-cell leukemia (ALL). These cells serve as a widely used model system for investigating T-cell receptor (TCR) signaling, activation, apoptosis, and leukemia biology. The Jurkat line expresses key T-cell surface markers and signaling molecules, making it a robust platform for interrogating signal transduction pathways relevant to adaptive immunity and hematologic malignancies.
Caveolin-1 (CAV1) encodes a scaffolding protein essential for caveolae formation, cholesterol-rich plasma membrane invaginations. It directly interacts with Src kinases (Lck, Fyn), H-Ras, eNOS, integrins, EGFR, and TGF-beta receptors, organizing signaling complexes in lipid rafts. Transcriptionally controlled by FOXO1, STAT3, TP53, and induced by TCR stimulation, cytokines (IL-2, IL-4), and cholesterol, CAV1 scaffolds key enzymes, inhibiting eNOS and modulating Src family kinases. In T cells, CAV1 coordinates proximal TCR-CD3 signaling, where it affects Lck and ZAP70 phosphorylation cascades that activate ERK1/2 and AKT, thereby linking caveolae to MAPK/ERK and PI3K/AKT pathways.
In the Jurkat model, CAV1 knockout disrupts caveolae-dependent membrane microdomain organization, thereby altering the compartmentalization of signaling intermediates. This loss-of-function model is particularly valuable for dissecting caveolin-1’s role in TCR-proximal events, including immune synapse formation and signal integration. Because deregulated CAV1 expression has been observed in T-ALL and other lymphoid malignancies, this knockout system provides a relevant context for probing how caveolin-1-dependent signaling influences leukemic cell proliferation, survival, and apoptosis. Moreover, the polyclonal nature avoids biases inherent in single-cell-derived clones, reflecting a more heterogeneous response akin to tumor heterogeneity.
Researchers can employ this CAV1 knockout population to investigate endocytic trafficking, such as transferrin uptake assays, and to screen for chemical or genetic modulators that restore or mimic caveolin-1 scaffolding functions. Phospho-flow cytometry measuring p-ERK and p-AKT enables quantitative assessment of TCR signaling strength, while co-immunoprecipitation studies can dissect altered protein?Cprotein interactions upon caveolin-1 loss. Additional applications include transcriptomic profiling via RNA-seq and functional apoptosis assays (Annexin V) to link caveolin-1 deficiency to T-cell fate decisions. For further technical details and experimental support, please contact Ascent Research.
